GLP-1 drugs could play surprising role in cancer outcomes

Key Points:

• The 2026 Cancer Progress Report by the American Association for Cancer Research highlights obesity as a major risk factor for many cancers and notes that GLP-1 medications, which promote weight loss and improve metabolic health, are being studied for their potential impact on cancer risk and outcomes.
• While some studies suggest GLP-1 receptor agonists like Ozempic and Wegovy may reduce cancer risk and improve survival, the overall evidence remains mixed, with some research indicating no effect or even increased risk for specific cancers such as thyroid cancer.
• Dr. Sai Yendamuri's research indicates that patients on GLP-1 medications undergoing lung cancer surgery or immunotherapy show lower cancer recurrence rates, potentially due to enhanced immune responses rather than a direct effect on cancer cells.
• The relationship between GLP-1 drugs, weight loss, and cancer outcomes requires further investigation, as not all patients experience significant weight loss, and it remains unclear if cancer benefits depend on this factor.
• Researchers are hopeful that future clinical trials may establish GLP-1 receptor agonists as part of cancer prevention and treatment strategies, alongside lifestyle modifications like exercise and weight management.